A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

May 27, 2026 updated by: C Ray Therapeutics

A Prospective, Open-label, Randomized, Phase 1/2 Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, randomized, open-label, phase 1/2 study on adult patients with PSMA-positive metastatic castration-resistant prostate cancer. Approximately 90 eligible participants will be enrolled and randomized 1:1:1 to three dose cohorts. The first six participants in each cohort will be assessed for dose-limiting toxicity (DLT) during the first treatment cycle.

Each eligible participant will receive one of the predefined doses of TRC003 (7.40, 9.25, 11.10 MBq) by intravenous infusion every 8 weeks (±1 week) for a maximum of 6 cycles if participants benefit from the treatment. All participants in this study may undergo dose modification based on the assessment of safety or efficacy by the investigators.

Any adverse events (AEs) observed or reported will be recorded. Blood and urine samples will be collected after the first administration of TRC003 on 6 participants in each cohort for pharmacokinetics (blood concentration of TRC003). 2 eligible participants of each cohort (total 6 participants) will undergo SPECT/CT for dosimetry after informed consent. All participants will be assessed PSA every 4 weeks. CT with contrast /MRI and bone scan will be evaluated every 8 weeks until proved disease progression by RECIST version 1.1 and the Prostate Cancer Clinical Trials Working Group 3 (PCWG3).

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
      • Shanghai, China, 200032
        • Not yet recruiting
        • Fudan University Shanghai Cancer Center
        • Contact:
        • Principal Investigator:
          • Dingwei Ye, MD, PhD
    • Shanxi
      • Taiyuan, Shanxi, China, 030013
        • Recruiting
        • Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital
        • Contact:
        • Principal Investigator:
          • Nianzeng Xing, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants must have the ability to understand and sign ICF.
  • Participants must have histological, and/or cytological confirmation of adenocarcinoma of the prostate.
  • Participants must have progressive mCRPC after treatment of ARPI or taxane-based chemotherapy.
  • Participant must have been diagnosed with mCRPC with documented progressive disease.
  • Participants must have prior orchiectomy and/or ongoing androgen-deprivation therapy with a castrate level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L).
  • Participants must have one or more PSMA-positive lesions whose PSMA uptake (SUVmax) is more than 2 fold of the blood pool.
  • Participants with an ECOG performance status of 0 - 2.
  • Participants must have adequate organ function
  • For participants who have partners of childbearing potential: Partner and/or patient must use a method of birth control with adequate barrier protection, deemed acceptable by the principal Investigator during the study and for 6 months after last investigational product administration.

Exclusion Criteria:

  • Participants with mixed histology of prostate cancer (e.g., neuroendocrine).
  • Any FDG-positive and PSMA-negative target lesions.
  • Any investigational agents and other concurrent chemotherapy, targeted therapy, biologic agents, immunotherapy, radioligand therapy (androgen-deprivation therapy excepted) within 28 days or 5 half-lives prior to day of administration, whichever is longer.
  • Previous treatment with any conventional external beam radiotherapy including hemi-body radiation within 6 weeks before enrollment.
  • Previous bone-targeted therapy cannot be taken with a stable dose within 4 weeks before enrollment.
  • Known hypersensitivity to the components of the study therapy or its analogs.
  • Transfusion for the sole purpose of making a participant eligible for study inclusion within 28 days before administration.
  • A superscan as seen in the baseline bone scan.
  • Concurrent serious (as determined by the Investigator) medical conditions.
  • Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 7.40MBq of TRC003
Participants will receive 7.40 MBq (200 μCi) ±10% of TRC003 by intravenous infusion every 8 weeks (±1 week) for a maximum of 6 cycles if participants benefit from the treatment.
Drug: Radiopharmaceuticals
TRC003 is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. TRC003 is a 225Ac-labeled novel molecule for targeted alpha therapy (TAT), which delivers alpha-particle radiation specifically to prostate cancer cells expressing PSMA. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them.
Experimental: 9.25 MBq of TRC003
Participants will receive 9.25 MBq (250 μCi) ±10% of TRC003 by intravenous infusion every 8 weeks (±1 week) for a maximum of 6 cycles if participants benefit from the treatment.
Drug: Radiopharmaceuticals
TRC003 is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. TRC003 is a 225Ac-labeled novel molecule for targeted alpha therapy (TAT), which delivers alpha-particle radiation specifically to prostate cancer cells expressing PSMA. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them.
Experimental: 11.10 MBq of TRC003
Participants will receive 11.10 MBq (300 μCi) ±10% of TRC003 by intravenous infusion every 8 weeks (±1 week) for a maximum of 6 cycles if participants benefit from the treatment.
Drug: Radiopharmaceuticals
TRC003 is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. TRC003 is a 225Ac-labeled novel molecule for targeted alpha therapy (TAT), which delivers alpha-particle radiation specifically to prostate cancer cells expressing PSMA. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence and severity of AEs and SAEs
Time Frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
Adverse events (AEs) will be assessed and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) by monitoring adverse events, laboratory tests, vital signs, Electrocardiogram(ECG).
From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
Prostate Specific Antigen response (PSA50)
Time Frame: About 12 months.
The percentage of participants who achieved ≥ 50% decrease from baseline at 12 weeks after the first administration or later.
About 12 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak concentration (Cmax)
Time Frame: 10 days following the first dose.
The maximum measured concentration of TRC003 in the body after administration.
10 days following the first dose.
AUC0-t
Time Frame: 10 days following the first dose.
Area under the concentration-time curve from time 0 to the last measurable concentration
10 days following the first dose.
T1/2
Time Frame: 10 days following the first dose.
Time required for the drug concentration to decrease by 50%.
10 days following the first dose.
Absorbed dose coefficients
Time Frame: 10 days following the first dose.
The ratio of absorbed dose in a target tissue to the total activity injected, representing dose delivered per unit activity.
10 days following the first dose.
Residence time
Time Frame: 10 days following the first dose.
The total time that TRC003 remains in a target organ or the body.
10 days following the first dose.
Effective dose
Time Frame: 10 days following the first dose.
Effective dose is the total radiation dose adjusted for organ sensitivity, used to estimate the risk of radiation-induced health effects.
10 days following the first dose.
Prostate Specific Antigen response (PSA90)
Time Frame: About 12 months.
The percentage of participants who achieved ≥ 90% decrease from baseline at 12 weeks after the first administration or later
About 12 months.
Biochemical Progression Free Survival (bPFS)
Time Frame: About 12 months.
Time to PSA progression by PCWG3 criteria (after decline from baseline: record time from start of therapy to first PSA increase that is ≥ 25% and ≥ 2 ng/mL above the nadir, and which is confirmed by a second value ≥ 3 weeks later).
About 12 months.
Overall Response Rate (ORR)
Time Frame: About 12 months
The proportion of participants with Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) from baseline until radiographic progression or death, whichever comes first.
About 12 months
Disease Control Rate (DCR)
Time Frame: About 12 months.
The proportion of participants with BOR of confirmed CR, PR, Stable Disease (SD) or non-CR/non-progressive disease (PD) from baseline until radiographic progression or death, whichever comes first.
About 12 months.
Duration of Response (DoR)
Time Frame: About 12 months.
Time between the date of first documented response and the date of first documented radiographic progression or death due to any cause by RECIST v1.1 and PCWG3 criteria.
About 12 months.
Time to first radiographic Soft Tissue Progression (TTSTP)
Time Frame: About 12 months.
Time to radiographic soft tissue progression by RECIST v1.1 and PCWG3 criteria.
About 12 months.
Time to Progression (TTP)
Time Frame: About 12 months.
Time to the first documented radiographic progression by RECIST v1.1 and PCWG3 criteria.
About 12 months.
Time to first Symptomatic Skeletal Event (TTSSE)
Time Frame: About 12 months.
Time to the first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.
About 12 months.
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time Frame: About 12 months.
A qusetionnaire to assess health-related quality of life (HRQOL) in cancer patients by patient-reported outcome (PRO) measure. The standard range of EORTC QLQ-C30 is 0-100 points. For Functional Scales, higher score means better function, better health status, higher quality of life. For Symptom Scales & Single Symptom Items, higher score means more severe symptoms / greater burden.
About 12 months.
Functional Assessment of Cancer Therapy - Prostate (FACT-P)
Time Frame: About 12 months.
A disease-specific, patient-reported outcome (PRO) questionnaire designed to measure health-related quality of life (HRQoL) in men with prostate cancer. FACT-P Total Score range is 0-160. Higher score means better quality of life, fewer symptoms, better functional status.
About 12 months.
Brief Pain Inventory - Short Form (BPI-SF)
Time Frame: About 12 months.
A widely used, validated patient-reported outcome (PRO) tool designed to assess the severity of pain and the impact of pain on daily functioning. BPI-SF Total Score range is 0-110. Higher total score means worse overall pain and greater pain interference with daily life.
About 12 months.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiographic Progression Free Survival (rPFS)
Time Frame: About 12 months.
Time to radiographic progression with contrast CT/MRI, or death due to any cause by RECIST v1.1 and PCWG3 criteria.
About 12 months.
Overall Survival (OS)
Time Frame: About 24 months.
Time to death due to any cause.
About 24 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

C Ray Therapeutics

Investigators

  • Study Director: Yan Wu, MD, C Ray Therapeutics (Chengdu) Co., Ltd.
  • Study Chair: Dingwei Ye, MD, PhD, Fudan University Shanghai Cancer Center, Fudan University
  • Study Chair: Nianzeng Xing, MD, PhD, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 22, 2026

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2029

Study Registration Dates

First Submitted

April 24, 2026

First Submitted That Met QC Criteria

April 30, 2026

First Posted (Actual)

May 5, 2026

Study Record Updates

Last Update Posted (Actual)

May 29, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TR1189-2501-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

ICF will be shared from June 2026 to December 2029.

IPD Sharing Access Criteria

The International Committee of Medical Journal Editors (ICMJE) and its associated journal editorial staff.

IPD Sharing Supporting Information Type

  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe